Response Criteria

WHO Criteria (1979)

Measure the sum of the products of diameters (SPD), bidimensional
Complete Response: tumor not detected for at least 4 weeks
Partial Response: ≥50% reduction in the SPD from baseline also confirmed at 4 weeks
Progressive Disease: ≥25% increase in tumor size in one or more lesions
Stable Disease: Neither partial response nor progressive disease

Source:

WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979

RECIST 1.0 (2000)

Measure the longest dimension, minimum size = 10mm at spiral CT, 20mm at conventional CT
Ten target lesions measured, 5 per organ
Complete Response: Disappearance of all lesions for >4 weeks
Progressive Disease: ≥ 20% increase from nadir
Partial Response: ≥ 30% decrease from baseline
Stable Disease: Neither partial response nor progressive disease

Source:

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16

RECIST 1.1 (2009)

Measure the sum of longest diameters (SOD) except in lymph nodes
Lymph nodes short axis: target lesions ≥15mm, non-target lesions = 10-15mm, non-pathological lesions < 10mm
Measure five target lesions (2 per organ); minimum size = 10mm
Complete Response: Disappearance of all target lesions for >4 weeks, any pathological lymph nodes (target or non-target) reduction in sort axis to <10mm
Partial Response: At least 30% decrease in the SOD
Progressive Disease: >20% increase in the SOD
Stable Disease: Neither partial response nor progressive disease

Source:

Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombeand J. Verweij (2009). "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)." European Journal of Cancer 45(2): 228-247

Immune-Related RECIST (iRECIST)

Modification of RECIST v1.1
Measure the longest diameter, minimum size = 10mm, except for lymph node
Lymph node short axis, minim size = 15mm
Measure five target lesions (2 pre organ); minimum size = 10mm
Complete Response: Disappearance of all lesions, and all nodes < 10mm
Partial Response: ≥30% decrease from baseline
Progressive Disease: ≥20% increase from the nadir
Stable Disease: Neither partial response nor progressive disease

Source:

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013). Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical cancer research: an official journal of the American Association for Cancer Research, 19(14), 3936–3943. doi:10.1158/1078-0432.CCR-13-0895

Immune-Related Response Criteria (irRC)

Measure the sum of the products of diameters (SPD), minimum size = 5mm x 5mm, bidimensional
Ten target lesions measured, 5 per organ
Complete Response: Disappearance of all lesions
Partial Response: ≥50% decrease from baseline
Progressive Disease: ≥25% increase from the nadir

Source: